Using the Comprehensive Complication Index to Rethink the ISGLS Criteria for Post-hepatectomy Liver Failure in an International Cohort of Major Hepatectomies.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
01 03 2023
Historique:
pmc-release: 01 03 2024
pubmed: 17 12 2021
medline: 9 2 2023
entrez: 16 12 2021
Statut: ppublish

Résumé

To compare different criteria for post-hepatectomy liver failure (PHLF) and evaluate the association between International Study Group of Liver Surgery (ISGLS) PHLF and the Comprehensive Complication Index (CCI)" and 90-day mortality. PHLF is a serious complication following hepatic resection. Multiple criteria have been developed to characterize PHLF. Adults who underwent major hepatectomies at twelve international centers (2010-2020) were included. We identified patients who met criteria for PHLF based on three definitions: 1) ISGLS, 2) Balzan (INR > 1.7 and bilirubin > 2.92mg/dL) or 3) Mullen (peak bilirubin >7mg/dL). We compared the 90-day mortality and major morbidity predicted by each definition. We then used logistic regression to determine the odds of CCI>40 and 90-day mortality associated with ISGLS grades. Among 1646 included patients, 19 (1.1%) met Balzan, 68 (4.1%) met Mullen, and 444 (27.0%) met ISGLS criteria for PHLF. Of the three definitions, the ISGLS criteria best predicted 90-day mortality (AUC = 0.72; sensitivity 69.4%). Patients with ISGLS grades B&C were at increased odds of CCI > 40 (grade B OR 4.0; 95% CI: 2.2-7.2; grade C OR 137.0; 95% CI: 59.2-317.4). Patients with ISGLS grade C were at increased odds of 90-day mortality (OR 113.6; 95% CI: 55.6-232.1). Grade A was not associated with CCI> 40 or 90-day mortality. In this diverse international cohort of major hepatectomies, ISGLS grade A was not associated with 90-day mortality or high CCI, calling into question the current classification of patients in this group as having clinically significant PHLF.

Sections du résumé

OBJECTIVE
To compare different criteria for post-hepatectomy liver failure (PHLF) and evaluate the association between International Study Group of Liver Surgery (ISGLS) PHLF and the Comprehensive Complication Index (CCI)" and 90-day mortality.
SUMMARY OF BACKGROUND DATA
PHLF is a serious complication following hepatic resection. Multiple criteria have been developed to characterize PHLF.
METHODS
Adults who underwent major hepatectomies at twelve international centers (2010-2020) were included. We identified patients who met criteria for PHLF based on three definitions: 1) ISGLS, 2) Balzan (INR > 1.7 and bilirubin > 2.92mg/dL) or 3) Mullen (peak bilirubin >7mg/dL). We compared the 90-day mortality and major morbidity predicted by each definition. We then used logistic regression to determine the odds of CCI>40 and 90-day mortality associated with ISGLS grades.
RESULTS
Among 1646 included patients, 19 (1.1%) met Balzan, 68 (4.1%) met Mullen, and 444 (27.0%) met ISGLS criteria for PHLF. Of the three definitions, the ISGLS criteria best predicted 90-day mortality (AUC = 0.72; sensitivity 69.4%). Patients with ISGLS grades B&C were at increased odds of CCI > 40 (grade B OR 4.0; 95% CI: 2.2-7.2; grade C OR 137.0; 95% CI: 59.2-317.4). Patients with ISGLS grade C were at increased odds of 90-day mortality (OR 113.6; 95% CI: 55.6-232.1). Grade A was not associated with CCI> 40 or 90-day mortality.
CONCLUSIONS
In this diverse international cohort of major hepatectomies, ISGLS grade A was not associated with 90-day mortality or high CCI, calling into question the current classification of patients in this group as having clinically significant PHLF.

Identifiants

pubmed: 34913896
doi: 10.1097/SLA.0000000000005338
pii: 00000658-202303000-00042
pmc: PMC9308484
mid: NIHMS1824194
doi:

Substances chimiques

Bilirubin RFM9X3LJ49

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e592-e596

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI125222
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA251070
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001871
Pays : United States

Investigateurs

Yuta Abe (Y)
Thomas Armstrong (T)
Alessandro Ferrero (A)
Carlos Corvera (C)
Koki Hayashi (K)
Taisuke Imamura (T)
Minoru Kitago (M)
Shoji Kubo (S)
Masatsugu Ishii (M)
Federico Mocchegiani (F)
Zenichi Morise (Z)
Kosuke Ogawa (K)
Yukiyasu Okamura (Y)
Shimpei Otsuka (S)
John Primrose (J)
Edoardo Rosso (E)
Fernando Rotellar (F)
Nadia Russolillo (N)
Shareef M Syed (SM)
Minoru Tanabe (M)
Shogo Tanaka (S)
Fumihiro Terasaki (F)
Marco Vivarelli (M)
Giuseppe Zimmitti (G)

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Références

Gilg S, Sandström P, Rizell M, et al. The impact of post-hepatectomy liver failure on mortality: a population-based study. Scand J Gastroenterol. 2018;53:1335–1339.
Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–724.
Balzan S, Belghiti J, Farges О., et al. The “50-50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:824–828.
Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg. 2007;204:854–862.
Skrzypczyk C, Truant S, Duhamel A, et al. Relevance of the ISGLS definition of posthepatectomy liver failure in early prediction of poor outcome after liver resection: study on 680 hepatectomies. Ann Surg. 2014;260:865–870.
Sultana A, Brooke-Smith M, Ullah S, et al. Prospective evaluation of the International Study Group for Liver Surgery definition of post hepatectomy liver failure after liver resection: an international multicentre study. HPB (Oxford). 2018;20:462–469.
Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213.
Slankamenac K, Graf R, Barkun J, et al. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258:1–7.
Kim SH, Hwang HK, Lee WJ, et al. Comprehensive complication index or Clavien-Dindo classification: which is better for evaluating the severity of postoperative complications following pancreatectomy? World J Surg. 2021;45:849–856.
Kowalewski KF, Müller D, Mühlbauer J, et al. The comprehensive complication index (CCI): proposal of a new reporting standard for complications in major urological surgery. World J Urol. 2020;39:1631–1639.
Clavien P-A, Vetter D, Staiger RD, et al. The Comprehensive Complication Index (CCI®): added value and clinical perspectives 3 years "Down the Line". Ann Surg. 2017;265:1045–1050.
Kauffmann R, Fong Y. Post-hepatectomy liver failure. Hepatobiliary Surg Nutr. 2014;3:238–246.
Mayhew D, Mendonca V, Murthy BVS. A review of ASA physical status -historical perspectives and modern developments. Anaesthesia. 2019;74:373–379.
Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251.
Nakanishi Y, Tsuchikawa T, Okamura K, et al. Risk factors for a high Comprehensive Complication Index score after major hepatectomy for biliary cancer: a study of 229 patients at a single institution. HPB (Oxford). 2016;18:735–741.
Sandini M, Paiella S, Cereda M, et al. Perioperative interstitial fluid expansion predicts major morbidity following pancreatic surgery: appraisal by bioimpedance vector analysis. Ann Surg. 2019;270:923–929.
Stata Corp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019.
Rahbari NN, Reissfelder C, Koch M, et al. The predictive value of postoperative clinical risk scores for outcome after hepatic resection: a validation analysis in 807 patients. Ann Surg Oncol. 2011;18:3640–3649.
Zheng Y, Yang H, He L, et al. Reassessment of different criteria for diagnosing post-hepatectomy liver failure: a single-center study of 1683 hepatectomy. Oncotarget. 2017;8:89269–89277.
Giani A, Cipriani F, Famularo S, et al. Performance of comprehensive complication index and Clavien-Dindo complication scoring system in liver surgery for hepatocellular carcinoma. Cancers (Basel). 2020;12:3868.
Birgin E, Tesfazgi W, Knoth M, et al. Evaluation of the new ISGLS definitions of typical posthepatectomy complications. Scand J Surg SJS Off organ Finnish Surg Soc Scand Surg Soc. 2019;108:130–136.
Liu JY, Ellis RJ, Hu QL, et al. Post hepatectomy liver failure risk calculator for preoperative and early postoperative period following major hepatectomy. Ann Surg Oncol. 2020;27:2868–2876.
Egeli T, Unek T, Agalar C, et al. The analysis of posthepatectomy liver failure incidence and risk factors among right liver living donors according to international study group of liver surgery definition. Transplant Proc. 2019;51:1121–1126.
Mizutani Y, Hirai T, Nagamachi S, et al. Prediction of posthepatectomy liver failure proposed by the international study group of liver surgery: residual liver function estimation with 99mTc-galactosyl human serum albumin scintigraphy. Clin Nucl Med. 2018;43:77–81.

Auteurs

Lucia Calthorpe (L)

School of Medicine, University of California San Francisco, San Francisco, CA.

Nikdokht Rashidian (N)

Department of Human Structure and Repair, Ghent University, Ghent, Belgium.

Andrea Benedetti Cacciaguerra (AB)

Department of Surgery, Poliambulanza Foundation Hospital, Brescia, italy.
Department of Surgery, University Hospital Southampton NHS Trust, Southampton, UK.

Patricia C Conroy (PC)

Department of Surgery, University of California San Francisco, San Francisco, CA.

Taizo Hibi (T)

Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.

Mohammad Abu Hilal (MA)

Department of Surgery, Poliambulanza Foundation Hospital, Brescia, italy.
Department of Surgery, University Hospital Southampton NHS Trust, Southampton, UK.

Daniel Hoffman (D)

Department of Surgery, University of California San Francisco, San Francisco, CA.

Keon Min Park (KM)

Division of Plastic Surgery, Department of Surgery, University of California San Francisco, San Francisco, CA.

Jaeyun Wang (J)

School of Medicine, University of California San Francisco, San Francisco, CA.

Mohamed Abdelgadir Adam (MA)

Department of Surgery, University of California San Francisco, San Francisco, CA.

Adnan Alseidi (A)

Department of Surgery, University of California San Francisco, San Francisco, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH